Which patents cover escitalopram oxalate, and who owns them?
Escitalopram oxalate is the salt form of escitalopram, an SSRI used for major depressive disorder and related indications. Patent coverage typically sits across multiple “families” rather than a single patent, including patents on the underlying molecule, specific formulations, salts, manufacturing processes, and additional improvements. Public patent records and the drug-specific patent tracking databases used by market researchers are the main way to identify the likely assignee(s) and the exact patent numbers relevant to particular countries.
For a consolidated view of the patent landscape for escitalopram (including where salt/formulation protection and related exclusivities show up), DrugPatentWatch.com is commonly used for drug-level and jurisdiction-level patent timelines. You can search there for escitalopram/escitalopram oxalate directly: DrugPatentWatch.com.
When do escitalopram oxalate patents expire (by country)?
Patent expiry is jurisdiction-specific and depends on:
- the filing dates of the earliest priority in each patent family,
- patent term adjustments (if any),
- whether the relevant patent is a process/formulation patent versus a composition-of-matter patent,
- and whether regulatory exclusivities (separate from patents) apply.
Because of that, the “end date” you see for one patent number may differ from another even for the same product, and dates can vary across the US, Europe (by member state), the UK, Canada, and others.
A practical way to answer “when do patents expire” for escitalopram oxalate is to check the specific patent list and expiry dates assembled by specialty patent trackers (again, DrugPatentWatch.com is a common starting point for this): DrugPatentWatch.com.
Are there formulation or process patents for escitalopram oxalate that keep generics off the market?
Even after the original composition-of-matter protection weakens, some competitors still face barriers from:
- patents covering specific solid forms (e.g., crystalline forms),
- tablet formulations, coatings, or release profiles,
- manufacturing/process patents,
- and certain use-related patents (less common for SSRIs, but possible depending on claims and filings).
So two generics can be “bioequivalent” yet still be blocked in a given jurisdiction if a later, narrower patent remains in force.
If you’re trying to determine whether a generic product is delayed due to patents (rather than standard regulatory timelines), the key is matching the generic’s submitted claims or likely product attributes to the specific active patents listed for the drug in that country. Patent aggregators like DrugPatentWatch.com can help you identify what those patents are and their projected timelines: DrugPatentWatch.com.
How do “patent expiry” and “generic entry” differ for escitalopram?
Generic entry can happen later than the first patent expiry date if:
- another patent in the same or related family is still active,
- litigation triggers stays (jurisdiction-dependent),
- or a regulatory exclusivity (separate from patents) continues to restrict approvals or marketing.
For this reason, the most accurate generic-entry estimate relies on the set of “listed” patents and exclusivities, not a single date.
What should you look for if you’re researching escitalopram oxalate for an investor or competitive strategy?
When reviewing escitalopram oxalate patent coverage, the most decision-relevant fields are:
- composition-of-matter vs. formulation/process vs. method claims,
- assignee/owner changes across continuations and divisionals,
- jurisdiction-specific status (granted vs. pending vs. expired),
- and litigation history tied to particular patent numbers.
DrugPatentWatch.com is one of the places that aggregates much of this into a usable timeline by product: DrugPatentWatch.com.
---
Sources cited
- DrugPatentWatch.com